DOCSLIB.ORG

10-25-06 Handouts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
10-25-06 Handouts Contraceptive Technology Faculty Update Leigh Beasley, MD, FAAFP Emory University Regional Training Center Satellite Conference and Live Webcast Atlanta, Georgia Wednesday, October 25, 2006 2:00 - 4:00 p.m. (Central Time) Produced by the Alabama Department of Public Health Video Communications and Distance Learning Division Program Objectives Program Objectives • Describe current thinking on • Describe the new World Health Organization's (WHO) medical contraceptive efficacy and the status eligibility criteria; Intrauterine Device of experimental contraceptives. (IUD) and teens, IUD and Plevic Inflammatory Disease (PID); • Describe the interrelationships of spermicides; and known medical contraception methods with thrombogenic mutations and oral specific drugs, reproductive contraceptives. disorders and other health problems. • Discuss management of common contraceptive problems. Contraceptive Use in the Half of All Pregnancies in the US: 2002 Report United States Each Year Are • Percentage of men and women who Unintended used contraception ranged from 67% Unintended Pregnancy- (Guam) to 88% (Idaho). Miscarriage 6% Unintended • Women reported OC’s as the Pregnancy- Intended Birth Pregnancy- predominant method in 49 areas 19% Birth 43% followed by tubals, condoms and vasectomy. • Men reported tubal, vasectomy, OC’s, Unintended and condoms. Pregnancy- Abortion Intended 23% Pregnancy- • Note lack of “new methods” in the top Miscarriage Pregnancies four. 9% (6.3 Million) 1 The Oral Contraceptive Cycle OC Developments • Progestin prevents luteinizing • New Progestin: Drospirenone; hormone (LH) surge. • Estrogen suppresses follicle- Yasmin. stimulating hormone (FSH) and follicular development. • Berlex has obtained FDA approval • Together, the hormones in for Yaz (20 mcg EE/3 mg combination OCs inhibit proliferative changes in drospirenone) for BC and PMDD uterus, leading to endometrial (unique dosing 24 days active pills atrophy. and 4 placebo pills). • When placebo pills are taken, a “pill period” results. OC Developments Depo-Provera • New Estrogen doses: 25mcg; • November 17, 2004: the FDA issued a Cyclessa, Ortho-Tricyclen Lo. “black box” warning recommending • Extended Cycle Use: Seasonale, that Depo-Provera be used long-term Seasonique. (i.e. more than two years) only if all • Widening EC use. other pharmacologic contraceptives • “Natural” estrogen pills and are not appropriate or tolerated due nonsteroidal progesterone agonist (tanaproget). to bone loss data in adult women. Depo-Provera and Effect of Contraception on BMD in Teens Bone Mineral Density • NIH-funded study (J. Adoles Health 2004) • Studied women ages 18-33 seeking – 370 girls (mean age, 15). contraception. – 53 chose Depo, 165 chose OC’s (20 ug of estrogen) and 152 chose no • Injectable Depo hormonal contraception. medroxypgogesterone acetate – BMD values after 12 months. 150mg vs. 0.030 mg EE plus 0.15 mg • At lumber spine: -1.4%, +2.3% and desogestrel vs. 0.035 mg EE plus 1.0 +3.8%. mg norethindrone vs. controls (no • At the hip: -2.2%, +0.3% and +2.3%. hormonal contraception). – Clinical relevance ? • Followed for 2 years. 2 Effects of Contraception on DMPA and Bone Health Bone Mineral Density • Three studies that indicate BMD is • Depo users-average loss from baseline comparable in former and never of 5.7 % (in spinal BMD). users following discontinuation of • Desogestrel OC-average loss form DMPA. baseline of 2.0 % (not statistically – Petitti DB et al (Obstet Gynecol significant). 2000;95:736-744). • Norethindrone- no significant change – Scholes D et al (Epidemiology in BMD. 2002; 13:581-587). • Controls-average gain of 2.6 % in BMD. – Scholes D et al (Arch Pediatr • Clinical relevance? Adolesc Med 2005; 159: 139-144). Effect of Pregnancy DMPA and Bone Health and Lactation on Bone • Data presented at the May 2005 Mineral Density ACOG meeting (co-author Andrew • Bone turnover is reduced in early Kaunitz, MD). pregnancy, returned to normal during the third trimester and increased in • Loss of BMD of approximately 1%- postpartum lactating women 2% annually, with slower loss after (Cole et al. 1987) that and substantial recovery • No evidence that high parity is following discontinuation (followed associated with an increased incidence patients for 2 years after DMPA was of osteoporotic fractures in later life discontinued). (Alffram, 1964; Walker et al. 1972). DMPA and Bone Health World Health Organization DMPA Statement • Complete recovery of BMD was not • July 2005: There should be no found at all skeletal sites assessed restriction on the use of DMPA, including no restriction on duration (but would it have if followed for > 2 of use, among women ages 18-45 years post DMPA?). who are otherwise eligible to use the method. 3 World Health Organization World Health Organization DMPA Statement DMPA Statement • Among adolescents (menarche to • Since the data are insufficient to less than 18) and women over 45, the determine if this is the case with long advantages of using DMPA generally term use among this age group, the outweigh the theoretical safety overall risks and benefits for continuing use of the method should concerns regarding fracture risk. be reconsidered over time with the individual user. Lower Dose, Subcutaneous Lower Dose, Subcutaneous Depo-Provera Depo-Provera • Study compared LDSQ Depo • Ovulation was suppressed in all (104mg/0.65ml) with IM Depo participants for at least 3 months. (150 mg/ml). • Median time to return to ovulation • Confirmed study participants were was similar in the two groups (183 ovulatory. days in the IM group and 212 days in • Received single injection and the SQ group). followed up until they ovulated • Dose and maximum serum (up to 12 months). concentration are substantially lower • 19 women who received IM and 39 with the SQ formulation…so ? Less received SQ were evaluated. side effects? NuvaRing NuvaRing®: Metabolic and • Non-biodegradable, flexible, Safety Conclusions transparent vaginal ring. • Minimal effect on lipid parameters. • Contains two active components: • No clinically relevant effect on ethinyl estradiol and etonogestrel (an estrogen and a progestin). carbohydrate metabolism. • Releases 0.015 mg/day of • Minimal effect on hemostatic ethinylestradiol and 0.120 mg/ day of variables, comparable with 30 EE/150 etonogestrel over a three week period. LNG COC. 4 NuvaRing®: Metabolic and Nuva Ring Update Safety Conclusions • Effectiveness not lower in very heavy • Low androgenic effects. women (Westhoff-ACOG 2005). • No adverse effect on blood pressure. • Continuous use can be based on a “calendar approach” since the Nuva • No unfavorable effects on the cervix Ring is active for 35 days, not 21 and vagina. (Timmer et al Clin Pharmokin 2000;39:233). • Clinicians can obtain free fitting rings by going to www.nuvaring.com California Women’s Health Emergency Contraception: Survey • 6198 women (age 18-44) were asked The Nations Best-Kept “If a woman has unprotected sex, is there anything she can do in the 3 Secret days after intercourse that will prevent pregnancy?” – Slightly more than _ said yes, 1/3rd said no and around 10% said they didn’t know. California Women’s Health Why Everyone Should Know Survey About EC 43% of the decrease in abortions in – 19% of those who answered yes • the US in the last 5 years has been listed incorrect responses to “what attributed to the use of EC. can she do?” (included RU 486 and • Up to 51,000 pregnancies are prevented annually by the use of EC. douche) and 7% gave ambiguous • (Finer et al. Perspec on Sexual answers (“seek medical help”). and Reprod health 2003) • Works like LAM. 5 Emergency Contraception EC’s Effects on Ovulation • Studied 58 women with regular Mechanism of Action menstrual cycles (either had tubals • Inhibition of ovulation. or IUD). • Decreases the probability of • Treatment regimens: two 0.75 mg fertilization after ovulation. doses of levonorgestrel (12 hours • Changes in the endometrium apart), single 0.75 mg dose of (decreasing the likelihood of levonorgestrel plus placebo or double dose of placebo. implantation). • Randomized to take meds when • Does NOT interfere with an leading follicle reached a diameter of established, post implantation 12-14 mm (Group I), 15-17 mm pregnancy. (Group II) and > 18 mm (Group III). EC’s Effects on Ovulation EC’s Effects on Ovulation • Within 5 days of treatment, there was • Percentage of cycle either ovualtory no ultrasound evidence of follicular dysfunction or no follicular rupture rupture (i.e., no ovulation) in 44%, was similar in with 3 regimens in 50% and 36% of cycles with 2 levo. Group 1, significantly higher with doses, 1 dose and placebo. levo than placebo in Group II and • Ovulatory dysfunction (disordered significantly higher with one dose surges in LH and FSH) in 35%, 36% levo than placebo in Group III. and 5%. EC’s Effects on Ovulation Emergency Contraception • Caution in interpreting results: used • Most effective if taken within 72 hormonal parameters and ultrasound hours of unprotected intercourse and did not test EC’s efficacy. (the sooner the better). • 13% of women with dominant follicle • New data suggests equal (i.e. > 18 mm) did not ovulate when effectiveness if both doses are taken treated with placebo. together and may be used up to 120 • Single dose used in this study was hours after unprotected intercourse. not the “single dose” used in • EC treatment is indicated regardless treatment studies. of the cycle day on which – (Contraception 2004 Dec.) unprotected intercourse occurred. 6 Emergency
Load more

Recommended publications
  • Sterilization and Abortion Policy Billing Instructions
    Sterilization and Abortion Policy Billing Instructions Table of contents Table of contents ...................................................................................................................................... 1 Hysterectomy ............................................................................................................................................ 2 Acknowledgement forms ..................................................................................................................... 2 Prior authorization requirements ......................................................................................................... 2 Covered services ................................................................................................................................... 2 Intrauterine Devices and Subdermal Implants ......................................................................................... 4 Family planning: sterilization .................................................................................................................... 4 Prior authorization requirements ......................................................................................................... 5 Covered services ................................................................................................................................... 5 Abortion .................................................................................................................................................... 6 Claim
    [Show full text]
  • Chapter 2 PET and SPECT Imaging of Steroid Hormone Receptors
    University of Groningen PET imaging of brain sex steroid hormone receptors and the role of estrogen in depression Khayum, Mohamed Abdul IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Publication date: 2015 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Khayum, M. A. (2015). PET imaging of brain sex steroid hormone receptors and the role of estrogen in depression. University of Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 27-09-2021 Chapter 2 PET and SPECT Imaging of Steroid Hormone Receptors Khayum MA, Doorduin J, Glaudemans AWJM, Dierckx RAJO, de Vries EFJ. PET and SPECT of Neurobiological Systems, R.A.J.O. Dierckx et al. (eds.) DOI 10.1007/978-3-642-42014-6_14, © Springer-Verlag Berlin Heidelberg 2014 Chapter 2 Abstract Steroid hormones like estrogens, progestins, androgens and corticosteroids are involved in normal brain function.
    [Show full text]
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 65 / No. 3 July 29, 2016 U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................2 How to Use This Document ...............................................................................3 Keeping Guidance Up to Date ..........................................................................5 References ................................................................................................................8 Abbreviations and Acronyms ............................................................................9 Appendix A: Summary of Changes from U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 ...........................................................................10 Appendix B: Classifications for Intrauterine Devices ............................. 18 Appendix C: Classifications for Progestin-Only Contraceptives ........ 35 Appendix D: Classifications for Combined Hormonal Contraceptives .... 55 Appendix E: Classifications for Barrier Methods ..................................... 81 Appendix F: Classifications for Fertility Awareness–Based Methods ..... 88 Appendix G: Lactational
    [Show full text]
  • Patient Instructions for Post-Vasectomy Fertility Test: Semen Specimen Collection
    Patient Instructions for Post-Vasectomy Fertility Test: Semen Specimen Collection Semen specimen 12 weeks after your vasectomy: Twelve weeks (3 months) after your vasectomy, you should collect a semen specimen in the container provided to you by the Urology Department. It is recommended that you have at least 20 ejaculations within the 12-week period after your vasectomy. Depending on the results of your initial sample, you may be asked by your physician to provide another sample. You must utilize an alternate method of contraception until cleared by your physician. You are considered fertile following vasectomy until, as per the American Urological Assn. recommendations, at least one semen analysis shows no fertile sperm. On rare occasions, the vasectomy can fail and the vas deferens tubes can rejoin. Your semen specimen can be brought by yourself to the Urology Clinic only if: It can be in the laboratory within one hour of collection, and It is kept at room temperature during that time. It is suggested, however, that you create your semen specimen while you are at the Urology Clinic. Your semen specimen deposit should be scheduled in advance by Kathy Stevens: call 434-924-9548 or 434- 924-9560. Please note the following important instructions and guidelines for semen collection: The sample should be collected after a minimum of 2 days, and a maximum of 7 days, of sexual abstinence. If you choose to collect the specimen at home, it must be collected in a clean specimen container with a secure lid, such as one with a screw-on cap.
    [Show full text]
  • Opinion Study on Vasectomy, Sterilized Version of Male Keywords: Vasectomy; Contraception; Sperm; Gonads Contraception
    Opinion iMedPub Journals Journal of Contraceptive Studies 2017 http://www.imedpub.com ISSN 2471- 9749 Vol. 2 No. 1:5 DOI: 10.21767/2471-9749.100028 Opinion study on Vasectomy, Sterilized Audrey Kanes Version of Male Contraception Department of Endocrinology, Universidad de São Paulo, Brazil Abstract Corresponding author: Audrey Kanes Vasectomy, it is well known heard around the world as the extreme perfect [email protected] sterilized process of contraception which is known to be synonym of contraception for males, male animals too. Amid vasectomy, a medicinal services supplier closes Professor, Department of Endocrinology, or obstructs the tubes that convey sperm. At the point when the tubes are shut, Universidad de São Paulo, Brazil. sperm can't leave a man's body and cause pregnancy. Sperms are made in the Gonads will go through two tubes called the vasa differentia to different organs Tel: +55 19 3521-7000 and blend with original liquids to frame semen. Vasectomy obstructs every vas deferens and keeps sperm out of the original liquid. Sperms are consumed by the body as opposed to being discharged. Without your thickened sperm (discharge) can't bring the suspect chance on pregnancy. Citation: Kanes A. Opinion study on Vasectomy, Sterilized Version of Male Keywords: Vasectomy; Contraception; Sperm; Gonads Contraception. J Contracept Stud. 2017, 2:1 Received: March 02, 2017, Accepted: March 09, 2017 Published: March 16, 2017 Sterilized Procedure There are diverse routes for men to be cleaned. One write does not require an entry point - a cut. Alternate sorts of vasectomy require an entry point. Cut strategies take around 20 min [1-3].
    [Show full text]
  • Sterilization As a Family Planning Method
    December 2018 | Fact Sheet Sterilization as a Family Planning Method Sterilization is a permanent method of contraception, and is the most commonly used form of family planning among couples both in the United States and worldwide. For men and women who no longer want to have children, sterilization offers a permanent, safe, cost-effective and efficacious way to prevent unintended pregnancy. Male sterilization is less common than female sterilization, but both are nearly 100% effective at preventing pregnancy. The Affordable Care Act’s no-cost coverage of sterilization has increased the affordability of the procedure for women, but it is still unclear the overall effect this will have on future utilization rates. Recent changes to insurance coverage policy, broader availability of long- acting contraceptives, as well as changes in the health care delivery system may reshape the choices that men and women make regarding the use of sterilization as a contraceptive method. This fact sheet explains the types of sterilization procedures available to women and men, reviews private insurance and Medicaid coverage policy, and discusses issues that affect availability in the U.S. Female Sterilization Female sterilization is an Figure 1 outpatient surgical Prevalence of Sterilization Among Women 15 to 44 Who procedure. The procedure Report Using a Reversible or Permanent Contraceptive blocks the fallopian tubes, Method, 2013-2015, by Selected Characteristics preventing eggs from All women, ages 15-44 22% travelling down the tubes to the uterus and blocking Ages 25-34 19% sperm from fertilizing the Ages 35-44 39% egg. Data from the Centers for Disease Control and Black 26% Hispanic 25% Prevention (CDC) show that White 21% among women ages 15 to 44 who use a contraceptive ≥ 200% FPL 16% method, one in five used ≤ 200% FPL 29% tubal ligation as their method 1 of contraception.
    [Show full text]
  • Family Planning, Sterilization and Abortion Services
    bmchp.org | 888-566-0008 wellsense.org | 877-957-1300 Reimbursement Policy Family Planning, Sterilization and Abortion Services Policy Number: 4.115 Version Number: 9 Version Effective Date: 07/01/2017 Product Applicability All Plan+ Products Well Sense Health Plan Boston Medical Center HealthNet Plan New Hampshire Medicaid MassHealth NH Health Protection Program Qualified Health Plans/ConnectorCare/Employer Choice Direct Senior Care Options Note: Disclaimer and audit information is located at the end of this document. Policy Summary The Plan reimburses covered family planning, sterilization and abortion items and services based on the provider’s contractual rates with the Plan and the terms of reimbursement identified within this policy. For information specific to genetic testing please reference the medical policies: Genetic Testing Guidelines and Pharmacogenetics, OCA 3.727, and Preimplantation Genetic Testing (Preimplantation Genetic Diagnosis and Pregenetic Testing), OCA 3.726. Prior-Authorization Please refer to the Plan’s Prior Authorization Requirements Matrix at www.bmchp.org. + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan. 1 of 8 Provider Reimbursement Abortion Services The Plan provides coverage for abortion services. Payment for an abortion service represents full compensation for these services, including the preoperative evaluation and counseling, laboratory and radiology services, surgery, and postoperative care. Family Planning Services The Plan will reimburse for medical services, laboratory services and drugs related to family planning services when provided to an eligible member in a facility licensed as a clinic or a hospital and under the supervision of a physician.
    [Show full text]
  • Inhibitors, Agonists, Screening Libraries
    www.MedChemExpress.com Inhibitors, Agonists, Screening Libraries Immunology Targeted Inhibitors Inhibitors Inhibitor Cocktails Compound Screening Libraries Disease Related Products Vitamin D Related Products Natural Products GPCR/G Protein Antibody-Drug Conjugate Related Products Epigenetics Cell Cycle/DNA Damage Cancer Cell Autophagy Stem Cells/Wnt Targeted Signaling 1)NJ% Inhibitors Pathways PI3K/Akt/mTOR MAPK/ERK Pathway Protein Tyrosine Kinase TGF-beta/Smad Antibody-Drug Compound Conjugates Screening Libraries MedChemExpress Contents About Us 2 About Us Overview of MCE MedChemExpress (MCE) offers a wide range of high quality research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. MCE has 3 Inhibitors knowledgeable and friendly customer service and technical support teams with years of experience in the life science industry. MCE will be a competent and trustworthy partner for your research and scientific projects. 5 Inhibitor Cocktails Quality Product quality is the key to our success and we take pride in offering only the highest-grade products. Product identity, quality, purity and activity are assured by our robust quality control and assurance polices, programs and 6 Screening Libraries procedures. We perform thorough analytical testing - including HNMR, LC-MS and HPLC - stability testing and activity assays on our products and the results from these tests are available to clients. 7 Disease Related Products Experience Vitamin D Related Products Our chemists are highly experienced in molecular synthesis and the preparation of large quantities of structurally diverse and synthetically challenging molecules. We work with clients that have widely different needs and we have 8 Natural Products been very successful in meeting such needs.
    [Show full text]
  • Progestin - Wikipedia, the Free Encyclopedia
    Progestin - Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Progestin From Wikipedia, the free encyclopedia A progestin is a synthetic[1] progestogen that has progestinic effects similar to progesterone. [2] The two most common uses of progestins are for hormonal contraception (either alone or with an estrogen), and to prevent endometrial hyperplasia from unopposed estrogen in hormone replacement therapy. Progestins are also used to treat secondary amenorrhea, dysfunctional uterine bleeding and endometriosis, and as palliative treatment of endometrial cancer, renal cell carcinoma, breast cancer, and prostate cancer. High-dose megestrol acetate is used to treat anorexia, cachexia, and AIDS-related wasting. Progesterone (or sometimes the progestin dydrogesterone or 17α-hydroxyprogesterone caproate) is used for luteal support in IVF protocols, questionably for treatment of recurrent pregnancy loss, and for prevention of preterm birth in pregnant women with a history of at least one spontaneous preterm birth.[3] They are also used in judicial chemical castration of sex offenders as well as a treatment options for those suffering from paraphilia. Co-inventor Luis E. Miramontes's signed laboratory notebook. October 15, 1951 1 History 2 Examples 3 Methods of progestin-based contraception 4 See also 5 References The recognition of progesterone's ability to suppress ovulation during pregnancy spawned a search for a similar hormone that could bypass the problems associated with administering progesterone (low bioavailability when administered
    [Show full text]
  • Explaining Contraception Job Aids English
    Explaining Contraception Job Aids for Healthcare Providers This resource was developed by Cardea, www.cardeaservices.org Expert review of this resource was provided by Dr. Christine Dehlendorf from the University of California, San Francisco. Funding for this resource was made possible by the Office of Population Affairs (Grant FPT-PA006028-01-00). The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services; nor does men- tion of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Explaining Contraception — Job Aids July 2017 Table of Contents Introduction 1 Explaining Contraception — Job Aids 3 Long Acting Methods Little or nothing for the user to do or remember, following initiation of the method with a provider. Sterilization Female sterilization .......................................................................3 Male sterilization .........................................................................5 Long-acting reversible methods Intrauterine Devices (IUDs) ...............................................................7 Implant .................................................................................9 User Controlled Hormonal Methods Require the user to do something related to the method daily/weekly/monthly/every 3 months. Require a prescription. Injectable (shot) ...........................................................................11 Pills ......................................................................................13
    [Show full text]
  • Comparing Effectiveness of Methods
    Com paring effectiveness of methods More effective Less than 1 pregnancy per 100 women in one year Implant IUD Female Vasectomy Sterilization UC Davis Obstetrics and Gynecology Appointments: (916) 734-6900 Injection – Lactational Pills Patch Vaginal For more information, visit our Depo-Provera Ring Amenorrhea website: https://health.ucdavis.edu/obgyn/ser vices/fp/ Even when people use birth control, they sometimes get pregnant when they don’t want to be. If that happens, your options would be to continue the Male Diaphragm pregnancy to parent a child, continue Female Fertility-Awareness the pregnancy and make an adoption Condoms Condoms Based Methods plan, or to have an abortion to end the pregnancy. Withdrawal Spermicide Less effective About 30 pregnancies per Adapted from WHO, 2007 100 women in one year Use of no contraception: about 85 pregnancies per 100 women in one year More Information about birth control methods available at UC Davis What is it? How Do I Get It? How Do I Use It? What Are the Advantages? What are the Disadvantages? STERILIZATION METHODS – Permanent. Last for the rest of your life Female or male Procedure which blocks or removes the Get It: A doctor performs a brief surgical Permanent methods mean you never have to worry You cannot change your mind and decide to get (vasectomy) woman’s fallopian tubes or a man’s vas procedure about birth control again pregnant later sterilization deferens eliminating sperm/ovum transfer Use It: Vasectomy requires a test to make sure Short-term pain or discomfort after procedure
    [Show full text]
  • WO 2012/055840 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . _ . 3 May 2012 (03.05.2012) WO 2012/055840 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) A61P 5/30 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/565 (2006.01) A61P 5/34 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/57 (2006.01) A61P 15/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, A61K 33/30 (2006.01) A61P 15/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/EP201 1/068596 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, 25 October 201 1 (25.10.201 1) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW. (26) Publication Langi English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/407,570 28 October 2010 (28.10.2010) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, (71) Applicant (for all designated States except US): BAYER RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, PHARMA AKTIENGESELLSCHAFT [DE/DE]; DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, Muller Strasse 178, 13353 Berlin (DE).
    [Show full text]